A Phase 2/3 interventional study of RoadMAB and Infliximab in Crohn Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 11 sites in United States. Open to participants aged 6 Years to 22 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati — 3 open to participants now, 4 under way, 1 of them phase 3. Crohn Disease · Children's Hospital Medical Center, Cincinnati.
Among the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2023, is one of 2 in phase 2/3, and was the 12th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →3 of the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati are open now, in 1 country. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 13–17
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 10+
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 6 Years to 22 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 2
First in 2005; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 180 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 54 across the 9 interventional studies, 160 across the 6 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
3 of the studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT07195123Children's Hospital Medical Center, CincinnatiEvaluation of the SMART IBD App in Pediatric IBD | 2027-02-28 |
| NCT06533228Children's Hospital Medical Center, CincinnatiHelmsley 3.0: Abbreviated MRE | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Crohn Disease by Children's Hospital Medical Center, Cincinnati, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment.
The main reason for this research study is to determine if a computer program that calculates an individualized dose based on a patient's blood testing results (precision dosing) can better achieve the best possible response to infliximab compared to standard dosing (conventional dosing).
This is an open-label, cluster randomized clinical trial to test whether precision infliximab dosing with a targeted concentration intervention is superior in achieving deep remission (endoscopic healing and clinical remission) compared to patients receiving conventional infliximab dosing.
With recognition that CD patients who achieve the "target" of deep remission with anti-TNF dose optimizations following pharmacodynamic monitoring had a significant reduction in CD-related adverse events, our central hypothesis is precision dosing with infliximab during induction and maintenance will achieve superior rates of deep remission vs. conventional care (control arm)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical activity and luminal inflammation, defined by both (1) and (2)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.
Drug: Infliximab
Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
Device: RoadMAB · Drug: Infliximab
The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL. Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
Also known as: Avsola, Inflectra, Ixifi, Remicade, Renflexis
Rate of Deep Remission
Pediatric Crohn's disease activity index (PCDAI) \<10 (child) or Crohn's disease activity index\<150 (adult), off prednisone/budesonide for \>8 weeks and Simple Endoscopic Scorer Crohn's Disease (SES-CD) SES-CD≤2
Time frame: Week 52
Rate of Steroid-free Clinical Remission
Pediatric Crohn's disease activity index (PCDAI) \<10 (child) or Crohn's disease activity index(CDAI)\<150 (adult) and off prednisone/budesonide for ≥4 weeks
Time frame: Week 14 and Week 52
Rate of Clinical Response
Decrease from baseline PCDAI of at least 12.5 points \& total PCDAI\<30 or a PCDAI\<10 (child) or a reduction of CDAI\>70 from baseline or CDAI\<150 (adult)
Time frame: Week 14 and Week 52
Rate of Primary Clinical Nonresponse
On prednisone \>16 consecutive weeks from start of infliximab or a PCDAI\>30 or CDAI\>220 for first four infusions
Time frame: Week 16
Rate of Primary Biologic Nonresponse
Failure to improve baseline fecal calprotectin by \>100 μg/g (limited to patients with a baseline fecal calprotectin \>250 μg/g) or Failure to improve baseline c-reactive protein ≥0.5 mg/dL (limited to patients with a baseline c-reactive protein \>1.0 mg/dL)
Time frame: Week 16
Rate of Sustained Steroid-free Remission
PCDAI\<10 (child) or CDAI\<150 (adult) at dose5 to week52 and off prednisone/budesonide from week 22-52
Time frame: Week 22 - Week 52
Rate of Steroid-free Remission -biomarker composite
PCDAI\<10 (child) or CDAI\<150 (adult), off prednisone/budesonide for ≥4 weeks, CRP≤0.5 mg/dL and fecal calprotectin \<250 μg/g
Time frame: Week 14 and Week 52
Rate of Endoscopic Healing
Simple endoscopic score-Crohn's disease (SES-CD) ≤2
Time frame: Week 52
Rate of Complete Endoscopic Healing
SES-CD=0
Time frame: Week 52
Rate of Endoscopic Remission
SES-CD\<4
Time frame: Week 52
Rate of Mucosal Healing
SES-CD≤2 and Ileal Global Histologic Activity Score (GHAS)/ Colon Global Histologic Activity Score (CGHAS) ≤2
Time frame: Week 52
PK Model Bias
Model predicted vs. actual infliximab concentration. Bias: mean predictive error (MPE)
Time frame: Week 0 - Week 52
PK Model Precision
Model predicted vs. actual infliximab concentration. Precision: root mean squared error (RMSE)
Time frame: Week 0 - Week 52
Rate of IBD related event - Fistula
Occurrence of fistula and presence of antibody to infliximab \>200 ng/mL
Time frame: Week 0 - Week 52
Rate of IBD related - Hospitalization
Occurrence of Crohn's disease related hospitalization
Time frame: Week 0 - Week 52
Rate of IBD related event - Surgery
Occurrence of Crohn's disease related surgery
Time frame: Week 0 - Week 52
Rate of IBD related event - Intestinal stricture
Occurrence of Crohn's disease related intestinal stricture
Time frame: Week 0 - Week 52
Rate of IBD related event - Starting corticosteroids
Occurrence of subjects starting a corticosteroid after week20
Time frame: Week 0 - Week 52
Rate of IBD related event - Antibodies to infliximab
Occurrence of antibodies to infliximab defined as \>200 ng/mL
Time frame: Week 0 - Week 52
Rate of Growth Restoration - Weight change
In Tanner stage I-III subjects: change in baseline weight (kg) by gender and age group
Time frame: Week 14 - Week 52
Rate of Growth Restoration- Height velocity
In Tanner stage I-III subjects: change in height velocity (z-score) by gender
Time frame: Week 14 - Week 52
PK of infliximab in pediatric patients
Measured infliximab clearance at baseline and at week52
Time frame: Week 0 - Week 52
Correlation between infliximab induction exposure and endoscopic remission
The correlation analysis to be performed for the total area under the curve (infliximab exposure, μg\*h/mL from week0-week14) and patients achieving endoscopic remission. Endoscopic remission is defined as a SES-CD≤2.
Time frame: Exposure Week 0 - Week 14, Efficacy Week 52
Correlation between infliximab induction exposure and deep remission
The correlation analysis to be performed for the total area under the curve (infliximab exposure, μg\*h/mL from week0-week14) and patients in deep remission. Deep remission is defined as a PCDAI\<10 (child) or CDAI\<150 (adult), off prednisone/budesonide for \>8 weeks and a SES-CD≤2.
Time frame: Exposure Week 0 - Week 14, Efficacy Week 52
Patient Reported Outcome-2 (PRO2) Response
\>50% improvement in total score from baseline
Time frame: Week 6, Week 14, Week 26, Week 52
Patient Reported Outcome-2 (PRO2) Remission
Stool frequency ≤3.0 and abdominal pain ≤1.0 (from baseline)
Time frame: Week 6, Week 14, Week 26, Week 52
Quality of Life & Disability -IMPACT-III score
Total IMPACT-III (child) score
Time frame: Week 52
Quality of Life & Disability - Inflammatory Bowel Disease Disk score
Total Inflammatory Bowel Disease Disk (without sexual function assessment) score
Time frame: Week 52
Quality of Life & Disability - Short Inflammatory Bowel Disease score
Total Short IBD Questionnaire (adult) score
Time frame: Week 52
Process Evaluation -Usability of Decision Support Tool
Total System Usability Scale score
Time frame: Week 0 - Week 52
Rate of Adverse events
Number of Adverse Events
Time frame: Week 0 - Week 52
Rate of Serious Adverse events
Number of Serious Adverse Events
Time frame: Week 0 - Week 52
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Mar 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →